Capricor Therapeutics: Another ‘Final’ 12-Month P2 DMD Trial Result (NASDAQ:CAPR)

0 6
Capricor Therapeutics Announces Another 'Final' 12-Month P2 Duchenne Muscular Dystrophy Trial Result Source link
Subscribe or log in to read the rest of this content.
Leave A Reply

Your email address will not be published.

At The Centre of Every Trade
$59.95/month